Long-term follow-up of patients with Philadelphia chromosome-positive chronic myeloid leukemia after stem cell mobilization under imatinib.
Theo D
TD
Kim
Michaela
M
Schwarz
Karl-Anton
KA
Kreuzer
Jaspal
J
Kaeda
Kamran
K
Movassaghi
Peggy
P
Grille
Peter T
PT
Daniel
Bernd
B
Dörken
Philipp
P
Le Coutre
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D013997:Time Factors; D055815:Young Adult
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate